The approval of ocrelizumab for primary progressive multiple sclerosis (PPMS) was groundbreaking, and more recently the MS community bore witness to another major breakthrough in MS management when siponimod was approved for secondary progressive MS (SPMS). Additionally, new investigational agents such as MD1003 (high-dose biotin) and masitinib are also being evaluated for treatment of PPMS, and clinical data for both show promise for patients with SPMS.
However, despite these advances, studies have shown that gaps in knowledge and performance exist among neurologists and their care team that pose a barrier to the integration of new and emerging therapies to treat MS in clinical practice.
This CME Outfitters Live and On Demand webcast will include an interactive, case-based panel discussion featuring expert faculty who will discuss the symptoms and clinical features of progressive MS, summarize its immunopathology and the mechanisms of action (MOAs) of new and investigational disease modifying therapies (DMTs), and evaluate the latest clinical evidence on the efficacy and safety of new and emerging therapies for SPMS and PPMS.
At the end of this CME/CE activity, participants should be able to:
The following learning objectives pertain only to those requesting CNE or CPE credit:
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Neurologists, MS specialists, PAs, NPs, nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Lublin reports that he receives research support from Actelion Pharmaceuticals; Biogen; Brainstorm Cell Therapeutics Inc; National Institutes of Health (NIH); National Multiple Sclerosis Society (NMSS); Novartis; and Sanofi. He has consulting agreements, serves on advisory boards, or Data and Safety Monitoring Board for Acorda Therapeutics; Actelion Pharmaceuticals/Janssen Pharmaceuticals, Inc.; Apitope; Brainstorm Cell Therapeutics Inc.; Atara Biotherapeutics, Inc.;Avotres; Biogen; EMD Serono, Inc; GW Pharmaceuticals; Immunic, Inc.; Innate Immunotherapeutics; Jazz Pharmaceuticals, Inc.; Mapi Pharma; MedDay Pharmaceuticals; MedImmune/ Viela Bio; Mylan; Novartis; Orion Biotechnology; Polpharma; Receptos, Inc./Celgene Corporation; Roche/Genentech, Inc.; Sanofi/Genzyme Corporation; Teva Pharmaceuticals; The Population Council, Inc. and TG Therapeutics. He is a speaker for Sanofi (non-promotional).
Dr. Miller reports he receives research support from F. Hoffmann-La Roche Ltd/Genentech, Inc.; Mallinckrodt; MedDay Pharmaceuticals; Novartis Pharmaceuticals Corporation; and Sanofi/Genzyme Corporation. He serves as a consultant for AbbVie: Inc.: Accordant Health Services (Caremark); Adamas Pharmaceuticals, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company/Celgene Corporation; Corrona; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Mallinckrodt; Mapi-Pharma; and Novartis Pharmaceuticals Corporation. He serves on the speakers’ bureau for Alexion Pharmaceuticals, Inc. (unbranded disease awareness programs only); Biogen Idec Inc. (unbranded disease awareness programs only); EMD Serono, Inc. (unbranded journal club); and Genentech, Inc. (unbranded disease awareness programs only).
Dr. Riley reports she receives research support from Biogen Idec Inc. She is a consultant for EMD Serono, Inc.; Genentech, Inc.: Novartis; and TG Therapeutics.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-062-H02-P.
Call us at 877.CME.PROS (877.263.7767).